Business Context and Reporting Period
This Form 8-K is a current report filed by Second Sight Medical Products, Inc. (not Vivani Medical, Inc.) on June 13, 2022. The registrant is incorporated in California and its common stock and warrants trade on Nasdaq under the symbols EYES and EYESW, respectively.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance data.
Material Changes
- Executive Departure: Dr. Jessy Dorn, Vice President of Clinical and Scientific Affairs, notified the company of her resignation effective July 15, 2022.
- Tenure: Dr. Dorn has served the company since 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is limited to the disclosure of the officer's departure under Item 5.02.
Investor Verification Checklist
- Verify the effective date of Dr. Dorn's resignation (July 15, 2022).
- Confirm the appointment of a successor for the Vice President of Clinical and Scientific Affairs role.
- Review recent 10-Q or 10-K filings for the most current financial performance data, as this 8-K contains none.
- Note the discrepancy in the request metadata: the filing is for Second Sight Medical Products, Inc., not Vivani Medical, Inc.